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Conclusions. Treatment weapons against cancer have allowed us to see long time survivors despite some genetic disorders that
leads to cancer. Studying biomolecular tumorigenic pathways in this patients may lead us to better understand the basis of
cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.170
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I present a case of meduloblastoma diagnosed en 1990, today a long term survivor for 22 years. The patient developed an atypical
meningioma 19 years after initial treatment and once again he is disease free following surgical resection and fractionated
stereotactic radiotherapy (FSRT). This is a 32 years old male patient. In 1990, at age nine, he was found to have a heterogeneously
enhancing posterior fossa mass with hydrocephalus. Gross total resection was performed and the tumor was consistent with a
classic medulloblastoma. Postoperative chemotherapy (VCR – CCNU) and 2D craniospinal radiation (34.2Gy/19 fr) with posterior
fossa 21.6Gy/12 fr boost was administered. The patient remained tumor free until November 2008, at which time he presented
with right sided weakness and numbness. MRI showed a supratentorial extra-axial mass located parasagittal into the left parietal
lobe, consistent with meningioma. Surgical resection of the tumor was undertaken on 01/22/10 and it was histopathologicaly
diagnosed as atypical meningioma WHO G2. Three months later MRI reveal a mass of 2.5 cm×2 cm×2.3 cm within the left
parietal lobe. FSRT was selected for reirradiation and 50.4Gy was delivered in 1.8Gy fractions to the gross tumor and surgical
bed PTV with 5 ﬁxed beams IMRT. He completed radiation treatments with only mild side effects but none of severe radiation
treatment late toxicities are presents today. I would note: (1) the radiation induced tumors risk after CNS irradiation; (2) the
treatment options for this condition with particular emphasis on curative reirradiation; (3) the patient status long time after
craniospinal irradiation and (4) the need of long-term follow-up for pediatric cancers survivors.
http://dx.doi.org/10.1016/j.rpor.2013.03.171
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Sister’s Mary Joseph nodule is a rare lesion, term is used since 1949 to indicate an umbilical coetaneous metastasis of a cancer,
most often intra-abdominal principally gastric or ovarian. It represents 30% of umbilical tumours. In 90% of cases, it is about an
adenocarcinoma. The origin of the cancer is the stomach (26%), ovary (12%), colon (10%), pancreas (7%), other localizations can
be at the origin of this umbilical metastasis: appendix, small intestine. We report case of a 63-year-old patient, operated 3 years
previously for épidermoïde carcinoma type basaloide of cervix stage IB2, without ganglions invasion, followed by a concomitant
radio chemotherapy 45Gy and a vaginal irradiation 20Gy The patient presented an umbilical nodule of 5 cm, without other lesion
en abdomen or pelvis. The surgical complete resection of the nodule allowed of conﬁrmed by anatomopathological study, the
carcinoma basaloide. The diagnosis of Sister Marie Joseph’s nodule was retained. After a resection we have complete response
at 17 months, despite the poor prognosis which Sister Marie Joseph’s nodule attests.
http://dx.doi.org/10.1016/j.rpor.2013.03.173
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Woman, 62 years old PPH: smoker, 20 cigarettes per day Oncological History: in 1998, after being studied by metrorrhagia and
tenesmus of three months’ duration, was diagnosed ST IIIB cervical squamous cell carcinoma. Physical examination: KI: 100
gynecological exploration: exophytic cervical mass of at least 7 cm in diameter, that bleeds at touch. VT: the lump described is
felt at the left side of the vagina down to its mid third. RE: left parametrium involvement. Oncological treatment: RTE-2D over
PTV (pelvis), isocentric, 4 ﬁelds, (2AP+2LAT) with photons of 25 MV. Dosage: 50Gy, later on, overprint PTV2 (left parametrium),
2 ﬁelds, (PA and AP) Dosage: 16Gy. DT 66Gy (5×200 cGy). Cervical overprint with endocavitary radiotherapy by means of a No.
1 convergent colpostate, bearer of 3 sources of 137 CS. Dosage 15Gy to 0.5 cm of the vaginal cuff. Concurrent with Cisplatin x
6 cycles. Treatment ends on september1998. Complete clinical response. Evolution: December 2003: elevated SCC: 3.4, CYFRA:
1.9, on the thoracic abdominal pelvic TC a 3 cm right pulmonary hilar mass was noted and affected mediastinic adenopathies,
the rest was normal. February 2004: diagnostic mediastinoscopy. PA: metastasic lymph nodes squamous cell adenocarcinoma.
Rescue treatment: RTE 3D composed of PTV1 (hiliar mass+medistinum), isocentric, 4 ﬁelds (PA, AP, OBP and OBA), with 18 MV
photons, dosage: 45Gy, overprint PTV2 (hiliar tumoral mass), 2 ﬁelds (OBP and LD), 18 MV photons, dosage 14.4Gy, DT:59.4Gy
